Core Insights - DXS International plc reported a revenue increase of 5% to £3,469,917 for the year ending April 30, 2025, compared to £3,308,359 in 2024, with a reduced loss of £94,750, significantly improved from a loss of £4,738,686 in the previous year [7][12][42] - The company is focused on delivering innovative healthcare solutions aligned with the NHS's digital transformation goals, particularly in addressing cardiovascular disease (CVD) and improving patient outcomes [6][18][36] - DXS is optimistic about future growth opportunities, particularly with the anticipated renewal of NHS central funding in April 2026, which is expected to enhance the adoption of its SMART Referral solution [15][36][80] Financial Highlights - Revenue increased by 5% to £3,469,917, with a loss for the year of £94,750, down from £4,738,686 in 2024, primarily due to increased amortization and impairment costs [7][12][42] - Available cash at the end of the period was £428,957, with unutilized debtor drawdowns of £245,043 [7] - R&D tax credits decreased from £212,964 in 2024 to £80,398 in 2025 due to new HMRC restrictions on overseas development claims [7][12][34] Operational Highlights - The SMART Referrals - Next-Gen solution is being deployed for final user acceptance testing in selected GP practices, marking a significant milestone for the company [15][16] - The ExpertCare Medicine Optimisation solution demonstrated excellent ROI for the NHS in managing hypertension, with plans for further rollout across Integrated Care Boards [17][36] - DXS continues to invest in R&D, with £705,292 spent in 2025, down from £992,828 in 2024, focusing on innovative solutions for the NHS [23][34] Industry Outlook - The NHS is under pressure to reduce waiting times and improve CVD management, with digital innovation and preventive care identified as key priorities in its Ten-Year Digital Transformation Plan [6][18] - The anticipated renewal of the NHS funding framework in April 2026 is expected to create new revenue opportunities for DXS as existing customers standardize on the SMART Referral platform [15][36][80] - DXS management remains committed to leveraging delays as opportunities for innovation and growth, aiming to enhance revenue and profitability for shareholders [19][36]